Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study - Ellis, Joanne; Maurik, Andre; Fortunato, Lea; Gisbert, Sophie; Chen, Keguan; Schwartz, Ann; McHugh, Simon; Want, Andrew; Santos Franco, Sara; Oliveira, Joao‐Joaquim; Price, Jeffrey; Coles, Alasdair; et al. (British journal of clinical pharmacology, 2019)
Keywords: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Autoimmune Diseases - drug therapy; Autoimmune Diseases - immunology; Double-Blind Method; drug safety; Female; Half-Life; Healthy Volunteers; Humans; immunology; Infusions, Intravenous; Interleukin-7 Receptor alpha Subunit - antagonists & inhibitors; Interleukin-7 Receptor alpha Subunit - immunology; Male; Middle Aged; monoclonal antibodies; Original; pharmacodynamics; pharmacokinetics; Placebos - administration & dosage; Placebos - adverse effects; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Young Adult; pharmacokinetics; immunology; pharmacodynamics; drug safety; monoclonal antibodies